Trial of Oxaloacetate in Alzheimer's Disease (TOAD)
Status:
Completed
Trial end date:
2018-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if oxaloacetate (OAA) is safe and tolerable at
doses of up to 2 grams per day in people with Alzheimer's disease (AD).